Insulet Corporation $PODD Holdings Lifted by Mitsubishi UFJ Trust & Banking Corp

Key Points

• Mitsubishi UFJ Trust & Banking Corp increased its stake in Insulet by 26.5% in Q4 to 43,921 shares (~$12.48M), and other institutions (notably Nordea, now holding 551,133 shares worth ~$157.1M) also materially boosted positions, signalling rising institutional accumulation.
• Despite several analyst downgrades and price-target cuts, Insulet retains a consensus rating of Moderate Buy with an average price target of $327.24 — well above the current trading level near $175.
• Insulet posted a quarterly beat (EPS $1.55 vs. $1.48 est.; revenue $783.8M vs. $768.3M) with revenue up 31.2% year-over-year, and an insider director purchased 2,030 shares, modestly increasing insider ownership.

Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 26.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,921 shares of the medical instruments supplier's stock after buying an additional 9,206 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned 0.06% of Insulet worth $12,484,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Winnow Wealth LLC bought a new position in Insulet during the third quarter worth $862,000. Nordea Investment Management AB boosted its position in Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier's stock worth $157,128,000 after purchasing an additional 142,922 shares during the period. Machina Capital S.A.S. bought a new position in Insulet during the third quarter worth $2,778,000. Jain Global LLC boosted its position in Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier's stock worth $32,945,000 after purchasing an additional 63,719 shares during the period. Finally, ING Groep NV boosted its position in Insulet by 88.5% during the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier's stock worth $5,341,000 after purchasing an additional 8,123 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have commented on PODD shares. Barclays reaffirmed an "underweight" rating and set a $286.00 price objective on shares of Insulet in a research report on Thursday, February 19th. Zacks Research cut shares of Insulet from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 5th. TD Cowen cut shares of Insulet from a "buy" rating to a "hold" rating and set a $294.00 target price for the company. in a research report on Monday, January 26th. JPMorgan Chase & Co. reduced their target price on shares of Insulet from $415.00 to $340.00 and set an "overweight" rating for the company in a research report on Thursday, February 19th. Finally, Citigroup cut shares of Insulet from a "buy" rating to a "neutral" rating and reduced their target price for the company from $338.00 to $230.00 in a research report on Tuesday, April 7th. Eighteen investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Insulet has a consensus rating of "Moderate Buy" and an average price target of $327.24.

Insulet Trading Up 1.7%

Shares of Insulet stock opened at $175.04 on Friday. The firm has a 50-day moving average of $216.37 and a 200-day moving average of $267.83. The stock has a market cap of $12.12 billion, a PE ratio of 50.01, a PEG ratio of 1.03 and a beta of 1.20. Insulet Corporation has a 52-week low of $158.35 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analysts' expectations of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. Insulet's quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.15 earnings per share. As a group, sell-side analysts forecast that Insulet Corporation will post 6.16 EPS for the current year.

Insider Buying and Selling

In related news, Director Michael R. Minogue purchased 2,030 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the purchase, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.36% of the stock is currently owned by company insiders.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.